Related Experiment Videos
Pravastatin--ocular side effects after a two year follow-up?
W Behrens-Baumann1, J Thiery, H G Fieseler
1Department of Ophthalmology, University of Goettingen, FRG.
Lens and Eye Toxicity Research
|January 1, 1990
Summary
Pravastatin effectively lowered LDL-cholesterol in patients with coronary heart disease over two years. No significant ocular side effects, such as cataracts, were observed during the study.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Hypercholesterolemia is a major risk factor for coronary heart disease (CHD).
- HMG-CoA-reductase inhibitors are a class of drugs used to lower cholesterol.
- Pravastatin is a novel HMG-CoA-reductase inhibitor.
Purpose of the Study:
- To evaluate the efficacy and safety of pravastatin in hypercholesterolemic patients with CHD.
- To assess the impact of pravastatin on plasma LDL-cholesterol concentrations.
- To monitor for any ocular side effects during long-term treatment.
Main Methods:
- A two-year prospective study involving 14 hypercholesterolemic patients with CHD.
- Administration of pravastatin to all participants.
- Regular monitoring of plasma LDL-cholesterol levels.
- Ophthalmological examinations to detect ocular side effects.
Main Results:
- Pravastatin treatment resulted in a significant reduction in plasma LDL-cholesterol by approximately 30-40%.
- No instances of cataract development were reported.
- No other ocular side effects were observed during the two-year follow-up period.
Conclusions:
- Pravastatin is an effective treatment for reducing LDL-cholesterol in hypercholesterolemic patients with CHD.
- Pravastatin demonstrates a favorable safety profile with no observed ocular toxicity over two years.
- Long-term pravastatin therapy may be a viable option for managing hypercholesterolemia in CHD patients.